Provided By GlobeNewswire
Last update: Mar 3, 2025
PRINCETON, N.J., March 03, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology clinical-stage company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today reported financial results for the full year ended December 31, 2024, and provided a corporate update.
Read more at globenewswire.comNASDAQ:PMVP (10/17/2025, 8:00:01 PM)
1.4
-0.04 (-2.78%)
Find more stocks in the Stock Screener